Idelalisib for treating refractory follicular lymphoma

3.1 Idelalisib is an oral treatment for follicular lymphoma. The marketing authorisation specifies a population with follicular lymphoma that is 'refractory to 2 prior lines of treatment'. However, the committee noted that the clinical evidence for idelalisib included a population in which there was a wide range in the numbers of prior chemotherapeutic regimens previously used by patients. Furthermore, the committee noted that the population considered in the company's submission was narrower than the population specified by the marketing authorisation, which is 'double-refractory'. This means that the follicular lymphoma has not responded, or showed only a limited response, to at least 2 previous treatments. The company specified that the previous treatments had to include an anti‑CD20 monoclonal antibody (rituximab or obinutuzumab) and chemotherapy containing an alkylating agent (for example, cyclophosphamide). The clinical experts considered this double-refractory population to have an unmet need for treatment options. The committee agreed with the company that idelalisib is likely to be used after an anti‑CD20 monoclonal antibody and an alkylating agent.

3.2 In the population that would be offered idelalisib (see section 3.1), most people are currently offered chemotherapy including (as listed in the NICE scope) cyclophosphamide-containing regimens, fludarabine-containing regimens, bendamustine and chlorambucil. The clinical experts explained that these vary in effectiveness and toxicity. The choice of chemotherapy regimen depends on individual circumstances, and takes into account previous chemotherapy, plus clinician and patient preference. Because of this, there is no single standard-of-care chemotherapy regimen in this population. The committee concluded that all the chemotherapeutic regimens listed in the scope were appropriate comparators.

3.3 The clinical experts stated that, after second-line treatment, people who could not have chemotherapy would be offered best supportive care instead. The clinical experts stated that some of those people could take idelalisib because it has a different toxicity profile to chemotherapy. So, while people may not tolerate the specific adverse effects of chemotherapy, they may tolerate those of idelalisib. The committee concluded that best supportive care is an option and a relevant comparator for people who cannot have chemotherapy, but who can take idelalisib.

3.4 The clinical experts stated that response to second-line treatment is consolidated with autologous stem cell transplantation in people who are considered fit enough, in line with NICE's guideline on non-Hodgkin's lymphoma: diagnosis and management. They also noted that, if a patient was healthy, autologous stem cell transplantation would be considered at later lines of therapy, as soon as the cancer responded to treatment. The clinical experts considered that autologous stem cell transplantation can improve prognosis, and that it could be used after idelalisib. The committee concluded that autologous stem cell transplantation was not a comparator to idelalisib, but that it was possible to use idelalisib as a bridge to autologous stem cell transplantation if there was a sufficient response to idelalisib. It also understood that patients could have a transplant before disease progression. The committee further concluded that it would need to consider the effects of autologous stem cell transplantation used after idelalisib or chemotherapy in the clinical- and cost-effectiveness results provided by the company.

3.5 The key clinical evidence for idelalisib came from the single-arm phase II DELTA study. This study included 125 patients with indolent (slowly growing) non-Hodgkin's lymphoma, 72 of whom had follicular lymphoma refractory to 2 or more lines of treatment. The primary outcome measured overall response rate. Overall survival and progression-free survival were among the secondary outcomes. DELTA had no control group; all patients in the study had idelalisib. The committee understood that this study was designed to show that idelalisib was a safe treatment. It also understood that the company had not carried out further effectiveness trials planned to support its application for a marketing authorisation (see section 3.6), which the European Medicines Agency granted on the basis of the DELTA study. The data from DELTA first provided by the company (cut-off date June 2015) showed an overall response rate of 55.6% and a median progression-free survival of 11.0 months; median overall survival was not reached, but the company estimated it to be 38.1 months. During consultation, the company submitted updated data based on a later cut-off date (August 2018); they showed that the median overall survival result was better than the company's original estimate (results are academic in confidence). The company stated that the latest data suggested that the overall survival benefit was largely as a result of survival after the cancer had progressed. The company supplemented the DELTA study with another source of evidence for idelalisib: the Compassionate Use Programme (CUP). This provided retrospective observational data from patients with follicular lymphoma having compassionate treatment in the UK and Ireland. The company took a subset of 79 patients with relapsed or refractory follicular lymphoma that had been treated with idelalisib. In these patients, median progression-free survival was 7.1 months, and median overall survival was not reached. The committee concluded that the evidence in DELTA and the CUP was not adequate enough for using to determine how well patients on idelalisib fared compared with people who had not taken idelalisib.

3.6 The committee discussed the lack of direct comparative evidence for idelalisib. The company explained that it had originally planned to develop a confirmatory randomised controlled trial after DELTA. However, the European Medicines Agency granted a marketing authorisation based on the non-comparative DELTA study. The company therefore chose not to pursue the planned studies of effectiveness of idelalisib in follicular lymphoma. The committee considered that this had resulted in an important gap in the evidence base for idelalisib, making it difficult to carry out an informed assessment of the effectiveness of idelalisib. It reflected that a randomised controlled trial in the intended population would help to resolve this. The committee concluded that the paucity of data, and the lack of comparative data, were key shortcomings to determining the clinical effectiveness of idelalisib compared with currently offered treatments in the NHS.

3.7 Despite the absence of a controlled trial, the committee discussed the evidence presented by the company. The committee discussed whether the populations in DELTA and the CUP are generalisable to people who take idelalisib in clinical practice:

3.8 Because the company had not done a controlled trial, it sourced evidence for comparators from a registry: the UK HMRN. This registry comprised a retrospective observational cohort. It included 26 patients with follicular lymphoma refractory to 2 previous lines of therapy, including rituximab and chemotherapy at first or second line, who had chemotherapy at third line. The committee noted that it was unclear whether the registry included a 'double-refractory' population and how many lines of chemotherapy each person had previously had. The committee was concerned that the HMRN population did not reflect the population defined for the current appraisal. The company did not have access to the data directly; instead, it requested analyses from the HMRN, based at the University of York. The company combined several comparators into a single chemotherapy comparator arm (see section 3.15). The original data cut (August 2013) submitted by the company for the committee's first meeting showed an estimated median progression-free survival of about 17 months, and a median overall survival of about 20 months. During consultation, the company submitted updated data based on a later data cut (August 2016), which showed that median overall survival was longer than the original data cut (detailed results are academic in confidence). The latest data cut had 34 patients, which the committee recognised as being a small number of patients; this number fell further in the matching analyses (see section 3.13 and section 3.15). The company explained that the analyses did not censor patients at transplantation. The committee understood that, because transplantation can improve prognosis (see section 3.4, not censoring patients at transplantation had the potential to invalidate clinical-effectiveness results. It acknowledged that it was likely that the HMRN was the only source of comparative data for the UK. Nevertheless, it concluded that the HMRN had limited value because it:

3.9 The company explained that it considered the DELTA population (that is, those having idelalisib) at baseline to have a worse prognosis than the HMRN population (that is, those having chemotherapy) at the time of reaching registry eligibility criteria. However, the clinical experts believed that the clinical practice-based HMRN population was likely to have a worse prognosis. The committee agreed that it was difficult to compare the 2 patient populations because of differences in baseline patient characteristics. It also agreed that the interplay of these differences made it difficult to judge which way overall population health would be biased. Either way, the committee appreciated that these differences could have confounded the association between treatment and survival. It considered the differences in how some variables had been defined between the 2 studies (see section 3.13), and that people in the HMRN had similar or worse disease in a shorter time from diagnosis. Based on these considerations, the committee concluded it more likely that patients in DELTA would have a better prognosis than those in the HMRN.

3.10 Based on the latest data for DELTA, idelalisib was associated with longer overall survival than was chemotherapy in the HMRN. However, these data showed that patients on idelalisib from 12 months onwards had a shorter progression-free survival than patients on chemotherapy. The committee agreed that shorter progression, then longer survival, was improbable. The company stated that it believed this counterintuitive result because of differences in the frequency with which each study measured disease progression. In both studies, progression-free survival was defined as 'time from initiation of treatment to date of first disease progression' or 'death from any cause'. However, in DELTA, patients had more regular scans compared with patients in the HMRN cohort; the company proposed that this is likely to have identified progression at an earlier stage for patients having idelalisib than having chemotherapy. The committee was not presented with data on the frequency of scanning in the HMRN cohort. The company stated that 'the HMRN dataset will systematically overpredict PFS [progression-free survival] in comparison to DELTA. Along with other issues of comparability across the two datasets, PFS comparison is rendered almost meaningless'. The ERG stated that this would have affected all methods of matching analyses submitted by the company (see section 3.12) equally because they all used progression-free survival from both samples. The company explained that the analyses did not account for stem cell transplantation before disease progression; specifically, it heard from the company that the analyses for progression-free survival did not censor patients at transplantation (see section 3.8). The committee considered that this may have biased the results. To address this issue, in some (but not all) of its analyses for cost effectiveness, the company assumed that the results for progression-free survival for chemotherapy and idelalisib were equivalent by using progression-free survival from DELTA in both treatment arms. The committee recognised that identifying progression at an earlier stage (for patients having idelalisib) was likely to have underestimated the treatment costs of idelalisib because people have idelalisib until disease progression (or unacceptable toxicities). The committee agreed that, in the absence of a trial, time to progression should reflect that seen in the NHS, that is, using data from the HMRN. The committee concluded that, in the absence of data, it was satisfied with the assumption that progression-free survival was equivalent between chemotherapy and idelalisib. However, it considered that the company should have taken estimates of progression-free survival from the HMRN, and not DELTA.

3.11 In the absence of a head-to-head randomised comparison of idelalisib with chemotherapy, in its original submission, the company compared progression and survival on idelalisib with the last line of chemotherapy before idelalisib, for DELTA and the CUP. The company used the time to progression with the previous line of chemotherapy (second line) as a proxy for time to progression with chemotherapy at third line (that is, when idelalisib would be a treatment option). The committee heard at the first meeting that the company did not perform a paired matching analysis. The committee was aware that the company used data from the CUP to compare idelalisib with previous lines of therapy but, at the second meeting, the company stated that it did not have access to the CUP data. The committee discussed several issues around the analysis:

3.12 In response to the consultation, the company submitted the following matching indirect comparisons using updated data (see section 3.5 and section 3.8) from DELTA and the HMRN:

3.13 The committee discussed the factors affecting prognosis that the 'updated' and 'reverse' matching adjusted indirect comparison analyses should have included (see section 3.12), and the sample sizes available. The committee was aware that it had not been presented with a systematic review of risk factors for progression and death. In addition to history of autologous stem cell transplantation (see section 3.4), the committee understood that there are other factors associated with progression and death. These include, but are not limited to, the components of FLIPI I and FLIPI II, notably: age, serum beta 2 microglobulin levels, bone marrow involvement, size of the largest involved lymph node, haemoglobin levels and the presence of bulky disease. Other factors include time in previous remission, time since completing the last therapy, comorbid conditions and previous chemotherapeutic agents. The clinical experts suggested that the FLIPI index is the best validated prognostic tool to use when diagnosing follicular lymphoma, but has limited value at third line. They proposed that a key prognostic indicator would be response to previous therapy, but this input was not captured in the variables chosen in the 'updated' matching adjusted indirect comparison. The company matched only 5 of 7 variables and assumed that these 5 accounted for all prognostic factors and treatment-effect modifiers. The committee was aware that a technical support document published by the Decision Support Unit recommends that, when only single-arm trial data are available, all the characteristics that could influence the outcomes of interest should be adjusted. However, increasing the number of matched characteristics reduced the effective sample size and the precision of the estimates, and the committee understood that the results were sensitive to this. For example, when the company removed the variable 'median time since diagnosis' from the analyses, estimated 2‑year overall survival fell by more than 20%. The committee also appreciated that there were unobserved differences between study populations that the analyses could not take into account. It noted that this would have biased the estimates of relative effectiveness if these unknown factors were associated with progression or death. The committee was satisfied that, in the 'reverse' matching adjusted indirect comparison, the company matched all 7 variables. However, in both 'updated' and 'reverse' comparisons, the committee noted that DELTA and the HMRN cohort defined 2 of the matched variables ('bulky disease' and 'time to diagnosis') differently, so the estimates of relative effectiveness from the 'updated' and 'reverse' comparison were likely to be biased. The committee was aware that the effective sample size for the 'reverse' matching adjusted indirect comparison was 26.7 people (26.7 represents a statistic rather than an actual number of people). The committee concluded that, although it preferred the 'updated' over the 'reverse' comparison, sparse data and potential confounding meant that the clinical-effectiveness results reflecting both were unreliable.

3.14 In response to the consultation, the company submitted 2 analyses with propensity scores using individual patient-level data from both DELTA and the HMRN, and using both populations applied as the 'treated group' (see section 3.12). The company matched all 7 variables (see section 3.13). The committee considered that matching on bulky disease and 'time to diagnosis' caused problems because each study defined those variables differently (see section 3.13). The committee noted that the propensity score matching analyses excluded patients without a suitable match (50% of patients in DELTA), which reduced the idelalisib sample size to 39 (DELTA as 'treated group') and 35 (the HMRN as 'treated group'). It also noted that the company submitted only 1 of many methods that can be used for propensity score matching, the 'three-nearest-neighbour' matching method (that is, matching baseline characteristics to the 3 closest patients in the comparison group). The company did not provide a rationale for its choice, nor had it conducted sensitivity analyses using alternative methods. The ERG commented that this was an important limitation because using other methods could change the results. In addition, the ERG noted that the summary measures from DELTA and HMRN groups using propensity matching were not as similar at baseline as they were in the 'updated' and 'reverse' matching adjusted indirect comparisons. The committee recognised that propensity scoring matches individual patient-level data together, rather than matching individual patient-level data to the mean, as was done in the matching adjusted indirect comparisons. Therefore, it did not expect comparable baseline characteristics between groups after matching. The ERG explained that, although all the analyses had problems, it preferred the 'reverse' to the 'updated' matching adjusted indirect comparison and propensity score matching analyses. However, the committee noted that sample sizes in the analyses using propensity score matching were more balanced across treatment arms than in the matching adjusted indirect comparisons, although they were small. The committee agreed that, because propensity score analyses match individual patient data for both populations, they provide more precise estimates than those from matching adjusted indirect comparisons. Despite this, the committee concluded that analyses using propensity score matching were associated with high levels of uncertainty. It also concluded that the matching comparisons submitted by the company did not provide the committee with robust information to evaluate the relative effectiveness of idelalisib compared with chemotherapy or best supportive care.

3.15 The committee was aware that the NICE scope listed the chemotherapeutic agents separately, and heard from the clinical experts that the therapies are likely to differ in effectiveness and tolerability. It recognised that the company had combined treatments together, which reflected a 'blended' comparator. The committee considered that evidence for the effectiveness of separate chemotherapeutic agents might exist from the trials that provided evidence for using chemotherapy, or from registries other than the HMRN. The Cancer Drugs Fund clinical lead considered that currently used individual chemotherapy regimens would be based on controlled clinical trial evidence. However, the committee also considered that this evidence might be difficult to source. At the second meeting, the company explained that it had not identified other registries or trials providing information on individual chemotherapy regimens. It further explained that it chose not to collect this information from the HMRN cohort because the sample size was already small (n=34, based on the latest data cut). The committee recalled that clinicians did not consider the chemotherapeutic regimens to be equally effective or have the same profile of adverse effects (see section 3.2). It understood that there were practical issues associated with estimating the effects of individual chemotherapy regimens. However, it noted that it had not been presented with evidence that justified the company's 'blended' comparator assumption that chemotherapeutic agents in UK practice could be considered similarly effective and tolerated, and at the same costs.

3.16 The committee recognised that the company did not provide data to describe the natural history of disease in patients having best supportive care. The committee asked the company whether the HMRN cohort could provide this, or whether clinical trial data were available from control arms of clinical trials of chemotherapy. The committee was aware that the company did not provide clinical data with which to compare idelalisib with best supportive care. Even so, the company compared idelalisib with best supportive care in its cost-effectiveness analyses by relying on an assumption that patients would progress instantly in the absence of an active treatment (see section 3.18).

3.17 The committee appreciated the company's attempts to reduce uncertainty in determining the clinical effectiveness of idelalisib compared with chemotherapy. The company did this by submitting longer-term data from DELTA and the HMRN, and by conducting additional indirect analyses, in response to concerns identified by the committee in the appraisal consultation document. However, the committee noted several concerns with the additional data and indirect analyses:

3.18 The company submitted 4 economic analyses using different model structures and sources of clinical data, which are summarised in table 1. In its models, the company used secondary endpoints (overall survival and progression-free survival) rather than the primary outcome from DELTA (overall response rate) to determine cost effectiveness.

Comparisons A, C and D reflected state transition models. In these, 'transition probabilities' determined the movements between states (clinical events) and time spent by patients in each state determined expected costs and quality-adjusted life years (QALYs). Comparison B used a 'partitioned survival analysis' approach in which survival curves (rather than transition probabilities) determined the proportion of patients in each state at each time point. The committee agreed in its first meeting that it would focus on comparisons A (the company's base case) and B; the company did not provide best supportive care data for comparison D. The committee noted that, in comparisons A and C, the company applied a 'hazard ratio' of 0.75 to adjust for the expected decline in the effectiveness of chemotherapy compared with idelalisib. This meant that, at each successive treatment line, patients would have expected their prognosis to worsen by 75% compared with the previous line of therapy. It also noted that the company had not justified its choice of the value of 0.75, which affected comparisons A and C to different extents. In its updated cost-effectiveness analysis submitted in response to the consultation, the company submitted results exclusively based on comparison B. It explained that, in its view, only this comparison could reflect the survival benefit of idelalisib after disease progression (see section 3.5). The committee preferred comparison B, but noted that all the comparisons were limited by:

3.19 The committee considered that using a blend of chemotherapeutic regimens (see section 3.15) as a comparator meant averaging the cost effectiveness of the treatments included, and potentially masked cost-ineffective individual treatments. The committee concluded that the cost effectiveness of idelalisib needed to reflect the comparison with each chemotherapy treatment individually.

3.20 The company submitted utility values to reflect health-related quality of life from a published study (Wild et al. 2006), even though it had collected quality-of-life data in DELTA. The ERG submitted scenario analyses with alternative utility values from other published studies (Bec et al. 2014 and the GADOLIN trial for non-Hodgkin's indolent lymphoma). The clinical experts agreed that all values seemed reasonable because people with follicular lymphoma can expect a good quality of life once the bulk of the disease has decreased. The committee was aware that DELTA collected health-related quality-of-life data using the Functional Assessment of Cancer Therapy - Lymphoma (FACT‑Lym) instrument (an extension of FACT - General [G]). This has 15 questions specific to patients with lymphoma. It was also aware that there is a mapping algorithm to map from FACT‑G to EQ‑5D, which the ERG requested of the company at the clarification stage. The company did not provide the mapped utilities, arguing that it was not useful because there was no mapping algorithm that specifically matched FACT‑Lym to EQ‑5D. The company added that the mapped utilities would have been limited to the clinical symptoms captured in EQ‑5D. The committee expressed its interest in seeing the mapped utilities in the appraisal consultation document, but the company chose not to submit the values at the second meeting. The committee concluded that it would have liked to see mapped utility values to validate literature-derived values, but that this would not have overcome the other problems associated with the clinical evidence.

3.21 The committee noted the adverse effects in people having idelalisib outlined in the European Medicine Agency's risk management plan, which include severe drug-related colitis, pneumonitis and organising pneumonia, and serious infections. The company did not provide relative safety data for chemotherapy. The clinical experts commented that adverse effects with chemotherapy are qualitatively different to those with idelalisib, so it is difficult to compare the safety profiles. The clinical experts commented that idelalisib is generally well tolerated. The committee considered that the adverse effects of chemotherapy are unlikely to differ between haematological malignancies, and thought that data from other malignancies would be valuable. The company included adverse events as disutilities within all the economic models. These disutility values were based on various sources and estimating the incidence using DELTA. The company models assumed the same incidence of adverse effects for both idelalisib and chemotherapy. The committee noted that adverse event disutility is not a key driver in the model. It concluded that idelalisib is unlikely to have the same effect on quality of life because of an adverse effect as chemotherapy, which themselves differed by individual regimen, but that this is unlikely to markedly affect cost-effectiveness results.

3.22 In its response to the consultation, the company submitted 3 deterministic incremental cost-effectiveness ratios (ICERs) for idelalisib compared with chemotherapy using comparison B (see section 3.18) incorporating a patient access scheme discount; probabilistic ICERs were broadly similar:

3.23 The committee considered that all matching analyses (see section 3.13 and section 3.14) were associated with high levels of uncertainty. It therefore would have liked to see the cost-effectiveness results associated with all matching analyses, which it considered would help to explore the effect of clinical-effectiveness uncertainty on the cost-effectiveness results. The committee noted that the company had not submitted cost-effectiveness analyses using the 'reverse' matching adjusted indirect comparison (see section 3.12 and section 3.22), even after NICE requested this. The ERG was not able to estimate pseudo-patient-level data for the 'reverse' matching adjusted indirect comparison (to estimate parametric survival curves). This was because the company did not submit numbers at risk or survival curves, and declined to provide a model with the option to choose between matching characteristics. At the second committee meeting, the company stated it had not submitted cost-effectiveness results for the 'reverse' matching adjusted indirect comparison because they would have been based on clinically implausible effectiveness data, so the results would have added to the uncertainty. The company further stated that it submitted the results only for the 'updated' matching adjusted indirect comparison because it had submitted these at the first meeting. The ERG carried out an exploratory analysis to give a crude estimate of an ICER for the 'reverse' matching adjusted indirect comparison. This estimated an ICER of £86,161 per QALY gained, which is well above what NICE normally considers to be an effective use of NHS resources. The committee concluded that it would take into account the ERG's exploratory analysis in its decision making.

3.24 The committee stated that it considered propensity score matching analyses to be more reliable than matching adjusted indirect comparisons or 'reverse' matching adjusted indirect comparisons, but all had problems (see section 3.13). However, it would have preferred to see estimates from the company using all the submitted clinical-effectiveness estimates. The committee noted that the ERG's exploratory analysis contained all the uncertainties associated with the company's model in addition to potential confounding (see section 3.18). It also recalled all the limitations associated with propensity score matching analyses (see section 3.14). It considered that the cost-effectiveness estimates lacked robustness and concluded that it needed to account for this in its decision making.

3.25 The committee appreciated that the company had submitted new clinical data and attempted additional indirect analyses. However, the committee noted that these additional data did not include any comparative evidence that appropriately adjusted for potential confounders. The analyses presented other problems including sparse data, matching on variables defined differently and analyses that did not censor patients having a transplant. The committee also appreciated that the ERG considered that, rather than reducing uncertainty, the company's additional data and analyses had instead increased uncertainty. The committee considered whether information from the clinical experts could inform estimates of overall survival with the new treatment (see section 3.17 and section 3.26). However, the company provided no data to support any estimates. Therefore, the committee concluded that idelalisib was not considered to represent a cost-effective use of NHS resource because of the range of ICERs presented (between £16,481 and £86,161 per QALY gained) and its concerns with the quality of the evidence.

3.26 The committee considered the advice about life-extending treatments for people with a short life expectancy in NICE's guide to the methods of technology appraisal:

3.27 Having concluded that idelalisib could not be recommended for routine use, the committee then considered whether it could be recommended for treating follicular lymphoma within the Cancer Drugs Fund. The committee discussed the arrangements for the Cancer Drugs Fund agreed by NICE and NHS England in 2016, noting NICE's Cancer Drugs Fund methods guide (addendum). It noted that, at the second meeting, the company had expressed an interest in providing idelalisib through the Cancer Drugs Fund. The company confirmed that there are no ongoing comparative trials to provide more robust, controlled evidence. The committee highlighted that, because no evidence showed that idelalisib improved length or quality of life, it encouraged research comparing idelalisib with individual chemotherapeutic regimens. The committee appreciated that the Cancer Drugs Fund is designed to resolve uncertainties, and that the key uncertainty in this appraisal was about the assumptions surrounding the comparative effectiveness of idelalisib with chemotherapy. It was aware that the Cancer Drugs Fund could collect data on the intervention (idelalisib), but not the comparator (chemotherapy), so would not resolve this uncertainty. Also, the committee had not seen reliable evidence that demonstrated idelalisib had 'plausible potential' to be cost effective (see section 3.24). It concluded that idelalisib could not be recommended for use within the Cancer Drugs Fund as an option for follicular lymphoma that had not responded to 2 previous lines of therapy in adults.

3.28 In its response to the appraisal consultation document, the company referred to NICE's technology appraisal guidance on daratumumab monotherapy, which was recommended through the Cancer Drugs Fund to treat relapsed and refractory multiple myeloma. It argued there was a parallel between the 2 appraisals because clinical evidence for daratumumab was limited to single-arm trials and an unanchored matching adjusted indirect comparison. The committee recalled that it had recommended daratumumab through the Cancer Drugs Fund because an Early Access programme is collecting data that have the potential to reduce several uncertainties identified by the committee (such as trial generalisability and place in the treatment pathway). The committee reiterated that the key uncertainty in the idelalisib appraisal was about the assumptions and analyses surrounding the comparative effectiveness, and the effectiveness and adverse effects associated with individual chemotherapeutic regimens, and that the Cancer Drugs Fund could not address these issues.

3.29 The committee noted that idelalisib is innovative in that it has a different mechanism of action to other available treatments for 'double-refractory' follicular lymphoma, and addresses an area of unmet clinical need (see section 3.1). The committee noted comments from the clinical experts that this different mechanism of action might bring psychological benefits for people reluctant to have more chemotherapy. It also noted that no evidence had been submitted to support this. The committee agreed that it could not determine whether the model captured quality-of-life improvements. It also agreed that an oral drug was preferable to an intravenous one. The committee concluded that idelalisib potentially reflects an innovative step change in treatment, but that it had not been presented with evidence to establish this.